Skip to content
UniqueBaseEN
For AI ↗
Companies

GT Apeiron

Developer of AI innovative drugs.

Visit website ↗
Snapshot

As of Oct 15, 2026, UniqueBase lists 1 funding record for GT Apeiron; the latest is $17.5M (Series A) on Mar 29, 2022.

Funding records
1
Latest round
$17.5M · Series A
Total raised (reported)
—
Rows with a source link
0 of 1

Overview

Pailong Biotech is an innovative drug developer using AI technology

Funding · 1

Funding

Amounts as reported; USD estimates shown only when they match

Listed 1 funding record. Latest funding: $17.5M (Series A), Mar 29, 2022.

Annual trendUnit: USD
2022$18MMar 29, 2022: $18M · Series A
DateAmountInvestorsSources
Mar 29, 2022$17.5M · Series APanacea Venture, 维亚生物 No source link

Select ▸ on a row to see its source brief and links.

Valuation · 1

Valuation

Amounts as reported; USD estimates shown only when they match

Listed 1 valuation record.

Annual trendUnit: USD

No chartable valuation estimates yet.

1 listed record lack a clear date or positive USD estimate for the chart.

DateAmountInvestorsSources
Mar 29, 2022— · Series APanacea Venture, 维亚生物 No source link

Select ▸ on a row to see its source brief and links.

Revenue

Revenue

Amounts as reported; USD estimates shown only when they match

No revenue records are listed yet.

No revenue rows to list.

Team, products & investors

Explore

More Industry apps companies

Sources · 0

Sources & provenance

English text is maintained separately from the original record. Consult the original source before citing a fact.

No source links are available for this profile.

Original source text

Names may use phonetic renderings when no English name is supplied. The original wording is retained below.

人工智能创新药物研发商 湃隆生物是一家基于人工智能技术的创新药物研发商